How Does Retatrutide Work?
Understanding the triple-agonist mechanism that sets retatrutide apart from other incretin-based therapies.
A Triple Hormone Receptor Agonist
Retatrutide (LY3437943) is a single peptide molecule engineered to activate three distinct hormone receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This triple-agonist approach is what makes retatrutide unique among the current generation of weight loss and diabetes medications.
Each of these receptors plays a different role in metabolism, and by engaging all three, retatrutide targets multiple pathways that contribute to weight regulation and blood sugar control.
The Role of Each Receptor
GLP-1 Receptor: Appetite and Blood Sugar
GLP-1 (glucagon-like peptide-1) is an incretin hormone released by the gut after eating. When retatrutide activates GLP-1 receptors, it reduces appetite and food intake by signaling satiety to the brain. It also slows gastric emptying, helping you feel full longer after meals. Additionally, GLP-1 receptor activation stimulates insulin secretion in a glucose-dependent manner, lowering blood sugar without causing dangerous hypoglycemia. This is the same receptor targeted by semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda).
GIP Receptor: Insulin and Fat Metabolism
GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that enhances insulin secretion from the pancreas. Beyond its role in glucose metabolism, GIP signaling appears to influence fat tissue biology and may improve how the body processes and stores lipids. The GIP receptor is also targeted by tirzepatide (Mounjaro, Zepbound), which combines GIP and GLP-1 agonism. Research suggests that adding GIP activation to GLP-1 may amplify weight loss and metabolic benefits beyond what GLP-1 alone achieves.
Glucagon Receptor: Energy Expenditure
The glucagon receptor component is what distinguishes retatrutide from dual agonists like tirzepatide. Glucagon, traditionally known for raising blood sugar by promoting glucose release from the liver, also increases energy expenditure and promotes hepatic fat oxidation — the breakdown of fat stored in the liver. By activating glucagon receptors, retatrutide may boost the number of calories the body burns and help reduce liver fat, a significant concern in people with obesity and metabolic syndrome.
Why Triple Is Potentially Better Than Dual or Single
The evolution of incretin-based therapies has followed a pattern of increasing receptor targets:
- Single agonists (e.g., semaglutide) target GLP-1 alone and produce approximately 15-17% weight loss.
- Dual agonists (e.g., tirzepatide) target GIP and GLP-1 and produce approximately 20-22% weight loss.
- Triple agonists (retatrutide) target GIP, GLP-1, and glucagon, and showed up to 24.2% weight loss in Phase 2 trials.
The hypothesis is that each additional receptor pathway contributes complementary mechanisms — appetite suppression from GLP-1, enhanced insulin and lipid handling from GIP, and increased energy expenditure from glucagon — leading to additive or synergistic metabolic benefits. Phase 3 trials will help determine whether this translates to clinically meaningful advantages.
How It Is Administered
Retatrutide is administered as a once-weekly subcutaneous injection, similar to semaglutide and tirzepatide. Its long half-life allows for weekly dosing, and treatment typically begins at a lower dose that is gradually increased over several weeks to reduce side effects.
For a deeper exploration of the science behind retatrutide's triple-agonist design, see our mechanism of action page.